10-(4-fluorophenyl)-3,3,6,6,9-pentamethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2h,5h)-dione and 10-(4-fluorophenyl)-3,3,6,6-tetramethyl-9-propyl-3,4,6,7,9,10-hexahydroacridine-1,8(2h,5h)-dione.
10-(4-fluorophenyl)-3,3,6,6,9-pentamethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione, C24H28FNO2, (I), crystallizes with two crystallographically independent molecules (which differ slightly in conformation), while 10-(4-fluorophenyl)-9-propyl-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione, C26H32FNO2, (II), crystallizes with one molecule per asymmetric unit. In both structures, the central ring in the acridine moiety is in a sofa conformation, while the outer rings adopt intermediate half-chair/sofa conformations. The central pyridine ring is orthogonal to the substituted phenyl ring. In both structures, the packing of the crystal is stabilized by C--H...O intermolecular hydrogen bonds.
Subbiah Pandi
A
A
Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India.
Velmurugan
D
D
Shanmuga Sundara Raj
S
S
Fun
H K
HK
Seshadri
P R
PR
Thirumalai
D
D
D000166:Acridines / Q000737:chemistry*; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D018360:Crystallography, X-Ray; D008958:Models, Molecular; D008968:Molecular Conformation
C435316:10-(4-fluorophenyl)-3,3,6,6,9-pentamethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2h,5h)-dione; C435317:10-(4-fluorophenyl)-3,3,6,6-tetramethyl-9-propyl-3,4,6,7,9,10-hexahydroacridine-1,8(2h,5h)-dione; D000166:Acridines; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents